IN8bio Inc. has unveiled a corporate presentation highlighting their advancements in the development of gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for oncology and autoimmune diseases. The company emphasizes the potential of γδ T cells, described as "Nature's CAR-T" cells, to directly kill cancer cells and orchestrate a broad immune response. IN8bio's T cell therapies aim to provide durable cancer remissions, with some patients experiencing over three years of progression-free survival. The presentation points out the precision and safety of γδ T cells, noting their lower rates of adverse events such as cytokine release syndrome and neurotoxicity. IN8bio's DeltExTM platform addresses key challenges in cell therapy and TCE development, while their γδ TCE construct is designed to efficiently deplete target cells and promote γδ T cell expansion. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.